Atomoxetine Versus Placebo for Cognitive Deficits in Stimulant Use Disorder: A Systematic Review
CONCLUSION: Despite a compelling neurobiological rationale and evidence of modest cognitive and mood benefits, atomoxetine has not demonstrated consistent efficacy as a monotherapy for StUD. Its favorable safety profile may…
Suggested reading